Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Roche Tries Again With Failed Huntington’s Drug Tominersen
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
Selling Consumer Division To Unilever Could Give ‘New GSK’ A Lift
Activist investors last year called for GSK to find an outright buyer for the consumer division, and may now get their wish.
Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.
Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy
CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.
Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.